Alta Sciences

APRIL 24, 2025

Case Study: How Altasciences Overcame Pharmacological Challenges in a GLP-1 IND-Enabling Study pmjackson Thu, 04/24/2025 - 21:43 For emerging therapies with pronounced pharmacological effects, thoughtful study design is critical to ensuring reliable and interpretable data. This blog was originally published in April 2025.

Small Molecule

BioPharma Drive: Drug Pricing

JULY 14, 2025

Published July 14, 2025 Ben Fidler Senior Editor post share post print email license Bain Capital, Kohlberg and Mubadala joined to invest in biopharmaceutical CDMO PCI Pharma on July 14, 2025. The company has 30 sites across Australia, Canada, North America, the U.K. and Europe, and, earlier this year, acquired a facility in San Diego.

Production

LifeSciVC

JANUARY 16, 2024

Small molecule GLP1s? Whether trial design, execution, or otherwise, drug development even where there is precedent is a challenging road and should not be taken for granted. Whether it’s small molecules to target the incretins (GLP1R ± GIPR), targeting well-validated signaling nodes in I&I (e.g.,

Small Molecule

Alta Sciences

FEBRUARY 10, 2025

Let Us Guide You Through the Process blussier Mon, 02/10/2025 - 17:54 HTML Let Us Guide You Through the Process Altasciences' experts streamline the IND/CTA application process by designing your regulatory strategy and thoroughly planning and completing your required preclinical studies.

Small Molecule

Fierce BioTech

JANUARY 3, 2025

Optimizing Formulation Strategies for Poorly Soluble Compounds: Insights into Bioavailability Enhancement and Accelerated Development dwunderlin Fri, 01/03/2025 - 15:54 Wed, 02/19/2025 - 11:00 Resource Type Webinar Feng Zhang, Ph.D. On Demand Start Date Wed, 02/19/2025 - 12:00 Hong Li, Ph.D.

Small Molecule

The Premier Consulting Blog

AUGUST 8, 2024

On July 31, 2024, the US Food and Drug Administration (FDA) announced Fiscal Year 2025 (FY2025) Prescription Drug User Fee Amendments of 2022 (PDUFA VII) fee rates for the review of human drug and biological product applications along with prescription drug program fees. i] United States Federal Register.

Drugs

New Drug Approvals

SEPTEMBER 13, 2024

2] [3] [4] A regulatory application for approval of the medication is expected to be submitted by 2025. [2] 4] [6] Aticaprant was originally developed by Eli Lilly , was under development by Cerecor for a time, and is now under development by Janssen Pharmaceuticals. [2] Drug Discovery. nM vs. 24.0 PMID 34826432.

Treatment

The Pharma Data

MARCH 28, 2022

By 2025, Dupixent is expected to generate an additional 11 new regulatory submissions across indications and age groups. These drug development programs include our acceleration of priority asset amlitelimab, an anti-OX40L antibody that aims to restore immune homeostasis between pro-inflammatory and anti-inflammatory T cells.

Small Molecule

BioPharma Drive: Drug Pricing

JUNE 23, 2025

Published June 23, 2025 Delilah Alvarado Staff Reporter post share post print email license A micrograph image of influenza A virus. The drug, an antiviral that combines a small molecule with a protein fragment, met its main and secondary goals in a Phase 2b trial. Influenza A virus" [Micrograph]. Retrieved from Flickr.

Drugs

Alta Sciences

MARCH 27, 2025

Altasciences Receives 2025 CDMO Leadership Award in Small Molecule Dosage Form Category pmjackson Thu, 03/27/2025 - 19:42 Laval, Qubec, March 27, 2025 Altasciences , a nine-time CRO Leadership Award winner, is proud to announce they have been awarded a 2025 CDMO Leadership Award in the Small Molecule Dosage FormNorth America category.

Small Molecule

Drug Target Review

MAY 30, 2025

Drug Target Review had the pleasure of attending SLAS Europe 2025 in Hamburg and what we saw was no mere showcase of cutting-edge tools, but a clear snapshot of where drug discovery is heading. So what really stood out at SLAS 2025? These are things the platform now enables. We dont just generate data for the sake of it.

Small Molecule

Drug Target Review

APRIL 11, 2025

Drug development is hampered by high costs, long timelines and a low probability of success and complex therapies exacerbate these challenges. Even excluding repositioned drugs, which could benefit from pre-existing toxicology and clinical data, a significant increase in PoS is still observed. This is an AI-generated image.

Clinical Development

LifeSciVC

FEBRUARY 18, 2025

At the risk of diving into the scientific weeds, what follows is an attempt to highlight the importance of these findings and their implications for drug development in muscular dystrophy. As such, the DGC and its underlying biophysical and mechanical properties have long been of high interest for academics and drug developers alike.

Small Molecule

Drug Target Review

APRIL 25, 2025

2 Liver CIVMs offer several benefits over conventional in vitro systems including prolonged functional activity, enhanced expression of various drug-metabolising enzymes and transporters, and improved cell-cell and cell-ECM (extracellular matrix) interactions. link] (accessed March 20, 2025). [13] 2024 [cited 2025 Apr 16].

Clinical Development

Codon

MAY 29, 2025

While small-molecule drugs continue to play a critical role in modern medicine, we are witnessing a shift toward the increasing development of amino acid-based therapeutics. Peptide-Based Drugs Sessile organisms, whether a sponge, coral, plant, or mushroom, are often quite literally between a rock and a hard place.

Drugs